Loading
TFEB (Transcription factor EB) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer and Melanoma.
Transcription factor that acts as a master regulator of lysosomal biogenesis, autophagy, lysosomal exocytosis, lipid catabolism, energy metabolism and immune response. Specifically recognises and binds E-box sequences (5'-CANNTG-3'); efficient DNA-binding requires dimerisation with itself or with another MiT/TFE family member such as TFE3 or MITF. Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the presence of nutrients, TFEB phosphorylation by MTOR promotes its cytosolic retention and subsequent inactivation.
CIViC holds 1 clinical evidence item and 0 assertions across 4 variants. Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.99, animal model 0.33, genetic association 0.34, somatic mutation 0.97).
In plain words · TFEB (Transcription factor EB) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer and Melanoma.
TFEB (Transcription factor EB) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer and Melanoma.
Transcription factor that acts as a master regulator of lysosomal biogenesis, autophagy, lysosomal exocytosis, lipid catabolism, energy metabolism and immune response.
No product in this corpus aims at TFEB yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA TFEB: RNA tissue enhanced (skeletal muscle 77 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas TFEB tissue; Open Targets ENSG00000112561 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Carr C.S. et al, Mol. Cell. Biol, 1990, "A helix-loop-helix protein related to the immunoglobulin E box-binding proteins". Source.
Sources: HGNC HGNC:11753 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P19484 (protein name, function text, keywords and locations (REST API)); CIViC gene TFEB (1 evidence items, 0 assertions, 4 variants; diseases: Renal Cell Carcinoma With MiT Translocations (GraphQL API, CC0)); Open Targets ENSG00000112561 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: melanoma 0.53, skin cancer 0.51, breast cancer 0.51 (GraphQL API, CC0))
Transcription factor that acts as a master regulator of lysosomal biogenesis, autophagy, lysosomal exocytosis, lipid catabolism, energy metabolism and immune response. Specifically recognises and binds E-box sequences (5'-CANNTG-3'); efficient DNA-binding requires dimerisation with itself or with another MiT/TFE family member such as TFE3 or MITF. Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the presence of nutrients, TFEB phosphorylation by MTOR promotes its cytosolic retention and subsequent inactivation. Upon starvation or lysosomal stress, inhibition of MTOR induces TFEB dephosphorylation, resulting in nuclear localisation and transcription factor activity. Specifically recognises and binds the CLEAR-box sequence (5'-GTCACGTGAC-3') present in the regulatory region of many lysosomal genes, leading to activate their expression, thereby playing a central role in expression of lysosomal genes. Regulates lysosomal positioning in response to nutrient deprivation by promoting the expression of PIP4P1. Location: Nucleus; Cytoplasm, cytosol; Lysosome membrane (UniProt). Locus 6p21.1 (HGNC).
RNA: tissue enhanced (skeletal muscle 77 nTPM), detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TFEB" OR ABSTRACT:"TFEB" OR TITLE:"transcription factor EB" OR ABSTRACT:"transcription factor EB" OR TITLE:"Transcription factor EB" OR ABSTRACT:"Transcription factor EB" OR TITLE:"TCFEB" OR ABSTRACT:"TCFEB" OR TITLE:"bHLHe35" OR ABSTRACT:"bHLHe35") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TFEB, not a curated reading list.